Cannabis compounds suppress immune defenses against gum disease bacteria through CB2 receptor pathway

All three major phytocannabinoids (CBD, CBN, THC) at physiological doses suppressed pro-inflammatory cytokine release (IL-12, IL-6, IL-8, TNF) and enhanced anti-inflammatory IL-10 in response to three oral pathogens. The effect operated through a common CB2/PI3K axis. In mice, CBD suppressed P. gingivalis-induced immune markers in wild-type but not CB2 knockout mice.

In vitro study exposing human innate immune cells and gingival keratinocytes to three oral pathogens with and without phytocannabinoids at physiological doses (1.0 mcg/ml). Pathway investigated through pharmaceutical inhibition and gene silencing. In vivo verification using wild-type and CB2 knockout mice.

Cannabis use is an established risk factor for periodontitis, but the mechanism was unknown. This study identifies a specific pathway: cannabinoids suppress the immune system's ability to fight the bacteria that cause gum disease, potentially allowing unchecked bacterial damage.

Cannabis is increasingly viewed as anti-inflammatory, which is often framed as beneficial. But in the context of oral infections, suppressing inflammation means suppressing the immune defense against bacteria, potentially worsening gum disease. The same anti-inflammatory property can be harmful in certain contexts.

In vitro study with in vivo mouse confirmation, not human in vivo data. Physiological relevance of the doses used may vary based on consumption method. Only three oral pathogens studied. Long-term periodontal outcomes not measured.